Insider Transactions in Q3 2023 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 07
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
4,166
-18.96%
|
$766,544
$184.52 P/Share
|
|
Aug 04
2023
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,057
-1.79%
|
$754,602
$186.95 P/Share
|
|
Aug 04
2023
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,460
-3.18%
|
$643,560
$186.95 P/Share
|
|
Aug 04
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
3,461
-5.39%
|
$643,746
$186.95 P/Share
|
|
Aug 04
2023
|
Akshay Vaishnaw President |
SELL
Open market or private sale
|
Direct |
4,057
-2.66%
|
$754,602
$186.95 P/Share
|
|
Aug 03
2023
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,941
+10.75%
|
-
|
|
Aug 03
2023
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,627
+17.82%
|
-
|
|
Aug 03
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
7,627
+27.19%
|
-
|
|
Aug 03
2023
|
Akshay Vaishnaw President |
BUY
Grant, award, or other acquisition
|
Direct |
8,941
+15.34%
|
-
|
|
Aug 03
2023
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
6,448
-4.67%
|
$1,186,432
$184.7 P/Share
|
|
Aug 02
2023
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,477
+50.0%
|
-
|